5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
CABG-related O
bleeding O
: O
Risk O
increases O
in O
patients O
receiving O
Effient O
who O
undergo O
CABG O
( O
5.2 O
) O
. O

* O
Discontinuation O
of O
Effient O
: O
Premature O
discontinuation O
increases O
risk O
of O
stent O
thrombosis O
, O
MI O
, O
and O
death O
( O
5.3 O
) O
. O

* O
Thrombotic O
thrombocytopenic O
purpura O
( O
TTP O
) O
: O
TTP O
has O
been O
reported O
with O
Effient O
( O
5.4 O
) O
. O

* O
Hypersensitivity O
: O
Hypersensitivity O
including O
angioedema O
has O
been O
reported O
with O
Effient O
including O
in O
patients O
with O
a O
history O
of O
hypersensitivity O
reaction O
to O
other O
thienopyridines O
( O
5.5 O
) O
. O

5.1 O
General O
Risk O
of O
Bleeding O
Thienopyridines O
, O
including O
Effient O
, O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
. O

With O
the O
dosing O
regimens O
used O
in O
TRITON-TIMI O
38 O
, O
TIMI O
( O
Thrombolysis O
in O
Myocardial B-NonOSE_AE
Infarction I-NonOSE_AE
) O
Major O
( O
clinically O
overt O
bleeding B-NonOSE_AE
associated O
with O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hemoglobin I-NonOSE_AE
> O
=5 O
g/dL O
, O
or O
intracranial B-NonOSE_AE
hemorrhage I-NonOSE_AE
) O
and O
TIMI O
Minor O
( O
overt O
bleeding B-NonOSE_AE
associated O
with O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hemoglobin I-NonOSE_AE
of O
> O
=3 O
g/dL O
but O
< O
5 O
g/dL O
) O
bleeding B-OSE_Labeled_AE
events O
were O
more O
common O
on O
Effient O
than O
on O
clopidogrel O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
bleeding B-OSE_Labeled_AE
risk O
is O
highest O
initially O
, O
as O
shown O
in O
Figure O
1 O
( O
events O
through O
450 O
days O
; O
inset O
shows O
events O
through O
7 O
days O
) O
. O

Figure O
1 O
: O
Non-CABG-Related O
TIMI O
Major O
or O
Minor O
Bleeding O
Events O
. O

Figure O
1 O
: O
Non-CABG-Related O
TIMI O
Major O
or O
Minor O
Bleeding O
Events O
. O

Suspect O
bleeding B-NonOSE_AE
in O
any O
patient O
who O
is O
hypotensive B-NonOSE_AE
and O
has O
recently O
undergone O
coronary O
angiography O
, O
PCI O
, O
CABG O
, O
or O
other O
surgical O
procedures O
even O
if O
the O
patient O
does O
not O
have O
overt O
signs O
of O
bleeding B-NonOSE_AE
. O

Do O
not O
use O
Effient O
in O
patients O
with O
active B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
, O
prior O
TIA B-Not_AE_Candidate
or O
stroke B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.1 O
, O
4.2 O
) O
] O
. O

Other O
risk O
factors O
for O
bleeding B-NonOSE_AE
are O
: O
* O
Age O
> O
=75 O
years O
. O

Because O
of O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
( O
including O
fatal B-NonOSE_AE
bleeding B-OSE_Labeled_AE
) O
and O
uncertain O
effectiveness O
in O
patients O
> O
=75 O
years O
of O
age O
, O
use O
of O
Effient O
is O
generally O
not O
recommended O
in O
these O
patients O
, O
except O
in O
high-risk O
situations O
( O
patients O
with O
diabetes B-Not_AE_Candidate
or O
history B-Not_AE_Candidate
of I-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
) O
where O
its O
effect O
appears O
to O
be O
greater O
and O
its O
use O
may O
be O
considered O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
Clinical O
Pharmacology O
( O
12.3 O
) O
, O
and O
Clinical O
Trials O
( O
14 O
) O
] O
. O

* O
CABG O
or O
other O
surgical O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Body O
weight O
< O
60 O
kg O
. O

Consider O
a O
lower O
( O
5-mg O
) O
maintenance O
dose O
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

* O
Propensity B-Not_AE_Candidate
to I-Not_AE_Candidate
bleed I-Not_AE_Candidate
( O
e.g. O
, O
recent O
trauma O
, O
recent O
surgery O
, O
recent O
or O
recurrent O
gastrointestinal B-Not_AE_Candidate
( I-Not_AE_Candidate
GI I-Not_AE_Candidate
) I-Not_AE_Candidate
bleeding I-Not_AE_Candidate
, O
active O
peptic B-Not_AE_Candidate
ulcer I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
or O
moderate O
to O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
) O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.7 O
, O
8.8 O
) O
] O
. O

* O
Medications O
that O
increase O
the O
risk O
of O
bleeding B-NonOSE_AE
( O
e.g. O
, O
oral O
anticoagulants O
, O
chronic O
use O
of O
non-steroidal O
anti-inflammatory O
drugs O
[ O
NSAIDs O
] O
, O
and O
fibrinolytic O
agents O
) O
. O

Aspirin O
and O
heparin O
were O
commonly O
used O
in O
TRITON-TIMI O
38 O
[ O
see O
Drug O
Interactions O
( O
7.1 O
, O
7.2 O
. O

7.3 O
) O
, O
and O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Thienopyridines O
inhibit O
platelet O
aggregation O
for O
the O
lifetime O
of O
the O
platelet O
( O
7-10 O
days O
) O
, O
so O
withholding O
a O
dose O
will O
not O
be O
useful O
in O
managing O
a O
bleeding B-NonOSE_AE
event O
or O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
an O
invasive O
procedure O
. O

Because O
the O
half-life O
of O
prasugrel O
's O
active O
metabolite O
is O
short O
relative O
to O
the O
lifetime O
of O
the O
platelet O
, O
it O
may O
be O
possible O
to O
restore O
hemostasis O
by O
administering O
exogenous O
platelets O
; O
however O
, O
platelet O
transfusions O
within O
6 O
hours O
of O
the O
loading O
dose O
or O
4 O
hours O
of O
the O
maintenance O
dose O
may O
be O
less O
effective O
. O

Figure O
1 O
5.2 O
Coronary O
Artery O
Bypass O
Graft O
Surgery-Related O
Bleeding O
The O
risk O
of O
bleeding B-OSE_Labeled_AE
is O
increased O
in O
patients O
receiving O
Effient O
who O
undergo O
CABG O
. O

If O
possible O
, O
Effient O
should O
be O
discontinued O
at O
least O
7 O
days O
prior O
to O
CABG O
. O

Of O
the O
437 O
patients O
who O
underwent O
CABG O
during O
TRITON-TIMI O
38 O
, O
the O
rates O
of O
CABG-related O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
were O
14.1 O
% O
in O
the O
Effient O
group O
and O
4.5 O
% O
in O
the O
clopidogrel O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
higher O
risk O
for O
bleeding B-OSE_Labeled_AE
events O
in O
patients O
treated O
with O
Effient O
persisted O
up O
to O
7 O
days O
from O
the O
most O
recent O
dose O
of O
study O
drug O
. O

For O
patients O
receiving O
a O
thienopyridine O
within O
3 O
days O
prior O
to O
CABG O
, O
the O
frequencies O
of O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
were O
26.7 O
% O
( O
12 O
of O
45 O
patients O
) O
in O
the O
Effient O
group O
, O
compared O
with O
5.0 O
% O
( O
3 O
of O
60 O
patients O
) O
in O
the O
clopidogrel O
group O
. O

For O
patients O
who O
received O
their O
last O
dose O
of O
thienopyridine O
within O
4 O
to O
7 O
days O
prior O
to O
CABG O
, O
the O
frequencies O
decreased O
to O
11.3 O
% O
( O
9 O
of O
80 O
patients O
) O
in O
the O
prasugrel O
group O
and O
3.4 O
% O
( O
3 O
of O
89 O
patients O
) O
in O
the O
clopidogrel O
group O
. O

Do O
not O
start O
Effient O
in O
patients O
likely O
to O
undergo O
urgent O
CABG O
. O

CABG B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
bleeding I-NonOSE_AE
may O
be O
treated O
with O
transfusion O
of O
blood O
products O
, O
including O
packed O
red O
blood O
cells O
and O
platelets O
; O
however O
, O
platelet O
transfusions O
within O
6 O
hours O
of O
the O
loading O
dose O
or O
4 O
hours O
of O
the O
maintenance O
dose O
may O
be O
less O
effective O
. O

5.3 O
Discontinuation O
of O
Effient O
Discontinue O
thienopyridines O
, O
including O
Effient O
, O
for O
active B-NonOSE_AE
bleeding I-NonOSE_AE
, O
elective B-NonOSE_AE
surgery I-NonOSE_AE
, O
stroke B-NonOSE_AE
, O
or O
TIA B-NonOSE_AE
. O

The O
optimal O
duration O
of O
thienopyridine O
therapy O
is O
unknown O
. O

In O
patients O
who O
are O
managed O
with O
PCI O
and O
stent O
placement O
, O
premature O
discontinuation O
of O
any O
antiplatelet O
medication O
, O
including O
thienopyridines O
, O
conveys O
an O
increased O
risk O
of O
stent B-NonOSE_AE
thrombosis I-NonOSE_AE
, O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

Patients O
who O
require O
premature O
discontinuation O
of O
a O
thienopyridine O
will O
be O
at O
increased O
risk O
for O
cardiac B-NonOSE_AE
events I-NonOSE_AE
. O

Lapses O
in O
therapy O
should O
be O
avoided O
, O
and O
if O
thienopyridines O
must O
be O
temporarily O
discontinued O
because O
of O
an O
adverse O
event O
( O
s O
) O
, O
they O
should O
be O
restarted O
as O
soon O
as O
possible O
[ O
see O
Contraindications O
( O
4.1 O
, O
4.2 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

5.4 O
Thrombotic O
Thrombocytopenic O
Purpura O
Thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TTP I-OSE_Labeled_AE
) O
has O
been O
reported O
with O
the O
use O
of O
Effient O
. O

TTP B-OSE_Labeled_AE
can O
occur O
after O
a O
brief O
exposure O
( O
< O
2 O
weeks O
) O
. O

TTP B-NonOSE_AE
is O
a O
serious O
condition O
that O
can O
be O
fatal B-NonOSE_AE
and O
requires O
urgent O
treatment O
, O
including O
plasmapheresis O
( O
plasma O
exchange O
) O
. O

TTP B-NonOSE_AE
is O
characterized O
by O
thrombocytopenia B-NonOSE_AE
, O
microangiopathic B-NonOSE_AE
hemolytic I-NonOSE_AE
anemia I-NonOSE_AE
( O
schistocytes B-NonOSE_AE
[ O
fragment B-NonOSE_AE
red I-NonOSE_AE
blood I-NonOSE_AE
cells I-NonOSE_AE
] O
seen O
on O
peripheral O
smear O
) O
, O
neurological B-NonOSE_AE
findings I-NonOSE_AE
, O
renal B-NonOSE_AE
dysfunction I-NonOSE_AE
, O
and O
fever B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.5 O
Hypersensitivity O
Including O
Angioedema O
Hypersensitivity B-OSE_Labeled_AE
including O
angioedema B-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
receiving O
Effient O
, O
including O
patients O
with O
a O
history O
of O
hypersensitivity B-Not_AE_Candidate
reaction I-Not_AE_Candidate
to O
other O
thienopyridines O
[ O
see O
Contraindications O
( O
4.3 O
) O
and O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

